Pilot Study of ACTH in the Treatment of Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
Status:
Completed
Trial end date:
2018-06-30
Target enrollment:
Participant gender:
Summary
This study is designed to answer whether patients with progressive IgA nephropathy, who
receive Acthar (ACTH) gel injection at a dose of 80 units subcutaneously twice weekly for 6
months is effective in inducing improvement in proteinuria and renal function.